Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NPK
London, United Kingdom
- Ownership
- Private
- Development stage
- Other
01
Overview
NPK Pharma is a clinical-stage biopharmaceutical company focused on developing innovative therapies for inflammatory and neurological conditions. The company primarily targets the neurokinin receptor system, with a lead program centered on Neurokinin 1 (NK1) receptor antagonists. Their research aims to address significant unmet needs in chronic pruritus, respiratory disorders, and dermatological conditions. By leveraging expertise in peptide and small molecule chemistry, NPK Pharma seeks to provide relief for patients suffering from refractory symptoms that do not respond to standard treatments.
- Therapeutic areas
- GastroenterologyPulmonologyDermatology
- Modalities
- Small moleculeBiologicPeptide
- Industry
- Biotech
Beyond the preview
Go deeper on NPK.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NPK.